Beyond checkpoint inhibitors: A new hope of personalized neoantigen vaccines for treatment of renal cell carcinoma
-
-
REFERENCES
[1] Braun D. A., Moranzoni G., Chea V., et al. (2025). A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639:474−482. DOI:10.1038/s41586-024-08507-5 [2] Lin M. J., Svensson-Arvelund J., Lubitz G. S., et al. (2022). Cancer vaccines: The next immunotherapy frontier. Nat. Cancer 3:911−926. DOI:10.1038/s43018-022-00418-6 [3] Yarchoan M., Gane E. J., Marron T. U., et al. (2024). Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1/2 trial. Nat. Med. 30:1044−1053. DOI:10.1038/s41591-024-02894-y [4] Rojas L. A., Sethna Z., Soares K. C., et al. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618:144−150. DOI:10.1038/s41586-023-06063-y [5] Jiang Q., Braun D. A., Clauser K. R., et al. (2025). HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell 188:1807−1827. DOI:10.1016/j.cell.2025.01.046 -
ABOUT THIS ARTICLE
Cite this article:
Zhang L., Ye F. and Wu M. (2025). Beyond checkpoint inhibitors: A new hope of personalized neoantigen vaccines for treatment of renal cell carcinoma. The Innovation Medicine 3:100133. https://doi.org/10.59717/j.xinn-med.2025.100133
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Zhang L., Ye F. and Wu M. (2025). Beyond checkpoint inhibitors: A new hope of personalized neoantigen vaccines for treatment of renal cell carcinoma. The Innovation Medicine 3:100133. https://doi.org/10.59717/j.xinn-med.2025.100133
Format
Content
DownLoad:
-
Figure 1.
Overview flowchart and key features of neoantigen-based PCV manufacturing, administration, and subsequent immune response evaluation plus clinical outcomes
